As filed with the Securities and Exchange Commission on January 29, 2026. Registration No. 333-292059 ________________________________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________________________________ STARTON HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) DELAWARE (Jurisdiction of incorporation or organization) _____________________ ...

Core Insights - MediciNova, Inc. has achieved significant progress in its SEANOBI study for MN-166 (ibudilast), with 100 patients enrolled, representing 50% of the target enrollment of 200 patients [1][2] - The SEANOBI Expanded-Access Program is funded by a $22 million grant from NINDS under the ACT for ALS initiative, aimed at providing treatment access to ALS patients not eligible for clinical trials while collecting valuable clinical data [2][4] - MN-166 is also being evaluated in the COMBAT-ALS Phase 2b/3 trial, with top-line results expected by the end of 2026 [3][5] SEANOBI Study - The SEANOBI study is designed to evaluate MN-166 in ALS patients and aims to enroll approximately 200 patients across 12 active sites [4] - The program focuses on generating real-world clinical outcomes and biomarker data, including neurofilament levels, to support future regulatory discussions [2][4] COMBAT-ALS Trial - The COMBAT-ALS trial is a randomized, placebo-controlled study assessing the efficacy and safety of MN-166, with 234 patients enrolled in the U.S. and Canada [3][5] - The trial includes a 12-month double-blind period followed by a 6-month open-label extension, with results anticipated by the end of 2026 [3][5] Company Overview - MediciNova is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and neurodegenerative diseases, with a late-stage pipeline including MN-166 and MN-001 [8] - MN-166 has received Orphan Drug Designation from the FDA and EMA, as well as Fast Track Designation from the FDA for ALS treatment [7][8]

Group 1 - Altimmune, Inc. has closed a registered direct offering of 17,045,454 shares, generating approximately $75 million in gross proceeds before fees and expenses [1][2] - The funds will be used for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and for general corporate purposes [2] - The offering was facilitated by Titan Partners, acting as the sole placement agent [3] Group 2 - Pemvidutide, Altimmune's lead candidate, is a dual-action therapy targeting glucagon and GLP-1 receptors, showing potential as a differentiated treatment for MASH [2][6] - The company has received Breakthrough Therapy Designation from the U.S. FDA for pemvidutide, indicating its significance in addressing serious liver diseases [2] - Altimmune is focused on delivering long-term value for shareholders while enhancing its operational flexibility through this investment [2]

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has initiated an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option for additional shares, subject to market conditions [1][2] Group 1: Offering Details - The public offering will include shares of common stock with a par value of $0.001, and the actual size and terms of the offering are not guaranteed [1] - Jefferies and Piper Sandler are serving as joint book-running managers for the offering [2] - Concurrently, Lexicon plans to conduct a private placement of common stock to Invus, L.P., its largest stockholder, which will not be registered under the Securities Act [3] Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offering primarily for the research and development of its drug candidates, as well as for working capital and general corporate purposes [4] Group 3: Regulatory Information - A shelf registration statement related to the offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]

Core Viewpoint - XTL Biopharmaceuticals Ltd. is actively working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc. and has scheduled a shareholders meeting to approve a private placement of up to US$2 million [1][2]. Group 1: Acquisition and Financial Strategy - The company has executed a Binding Letter of Intent on January 13, 2026, for the acquisition of NeuroNOS Ltd. [1] - The completion of this acquisition and the private placement is expected to address the company's deficiency under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity [2]. - A shareholders meeting is set for February 17, 2026, to approve the private placement [1]. Group 2: Company Overview - XTL Biopharmaceuticals Ltd. holds 100% of The Social Proxy Ltd. and has an intellectual property portfolio that includes hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) [3]. - The company is focused on strategic collaborations and acquisitions to enhance its therapeutic portfolio in high-value disease areas [3]. - XTL trades on the Nasdaq Capital Market and the Tel Aviv Stock Exchange [3].

Core Viewpoint - Argenx SE (NASDAQ:ARGX) is highlighted as one of the best stocks to buy, with a price target increase from Wells Fargo reflecting strong growth potential in its product Vyvgart [1][2]. Group 1: Price Target and Analyst Outlook - Wells Fargo raised the price target on Argenx SE from $1,264 to $1,317, maintaining an Overweight rating on the shares [1][2]. - Analyst Derek Archila increased the 2026-2030 outlook for Vyvgart by 5-15%, indicating confidence in the product's performance [2]. - The consensus estimate for Argenx's FY2026 revenue is projected at $5.6 billion, but Archila anticipates it will reach approximately $6.5 billion, driven by growth in subsequent quarters [3]. Group 2: Stock Performance and Analyst Sentiment - Over the past six months, Argenx SE's shares have increased by over 45% as of January 27 [4]. - Among 28 analysts covering ARGX, 86% have rated the stock as a Buy, with a median price target of $1,007.86, suggesting a potential upside of 16.80% [4].

Core Viewpoint - Ascendis Pharma A/S (NASDAQ:ASND) is recognized as one of the best stocks to buy for investment, with a Buy rating reiterated by BofA and a price target set at $246 [1]. Group 1: Analyst Ratings and Price Targets - BofA has maintained a Buy rating on Ascendis Pharma, with a price target of $246 [1]. - Wells Fargo analyst Derek Archila upgraded the price target for Ascendis Pharma from €322 to €330, while keeping an Overweight rating on the stock [2]. - Archila highlighted Ascendis Pharma's operating cash flow guidance of €500 million, excluding TransCon CNP, which suggests a revenue range of €1.1-€1.2 billion for Yorvipath [2]. Group 2: Product Development and Market Potential - The TransCon CNP combined with Skytrofa is expected to potentially become the standard of care over time, indicating significant upside for Ascendis Pharma [3]. - Skytrofa is currently used for treating pediatric growth hormone deficiency, while TransCon is being developed for achondroplasia [3]. - Ascendis Pharma focuses on developing TransCon-based therapies to meet unmet medical needs globally [3].

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the best stocks to buy for investment, highlighting its strong market position and potential for growth [1] Group 1: Analyst Ratings and Price Targets - H.C. Wainwright has reiterated a Buy rating on Halozyme, maintaining a price target of $90, reflecting confidence in the company's strategic and financial strength [2] - Morgan Stanley has slightly lowered its price target for HALO from $79 to $75 while keeping an Overweight rating, indicating a cautious but positive outlook on the stock [3] Group 2: Business Developments - Recent business developments with Takeda and Skye are viewed as significant wins for Halozyme, expanding the reach of its ENHANZE platform beyond oncology into larger markets such as inflammatory bowel disease and obesity [2] Group 3: Company Overview - Halozyme Therapeutics is a biopharmaceutical company focused on the research, development, and commercialization of proprietary enzymes and devices globally, positioning itself in a competitive industry [4]

Core Insights - Tevogen Bio Holdings Inc. is modifying its long-term stock incentive program to align with specific company milestones, including revenue targets, applicable to all eligible employees and consultants [1][7]. Company Overview - Tevogen has transitioned from a T cell therapy biotech to a diversified healthcare company, aiming to launch at least four blockbuster products by 2030 and generate revenue in 2026 through current programs, asset acquisitions, and joint ventures [2]. - The company operates on principles of affordability, efficiency, and scientific rigor, utilizing advanced AI and precision T cell therapy platforms to develop life-saving therapies across various therapeutic areas [2]. Product Development - Tevogen Bio's lead initiative has successfully completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology based on the proprietary ExacTcell™ platform [3]. - Tevogen.AI aims to enhance drug development by improving target detection, reducing failure rates, and optimizing clinical trial designs through predictive technologies, leveraging cloud services from major tech providers [4]. Strategic Initiatives - The company is exploring future initiatives that may encompass domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to promote sustainable innovation and broaden patient access to healthcare [5].

Core Viewpoint - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is highlighted as one of the best stocks to buy, with a recent price target increase from H.C. Wainwright indicating strong future potential for the company [1][2]. Group 1: Price Target Adjustments - H.C. Wainwright raised its price target on Mirum Pharmaceuticals from $102 to $130, maintaining a Buy rating, marking the second increase in two weeks [1][2]. - The price target revisions are based on bullish guidance for 2026, particularly regarding the clinical evaluation of volixibat in chronic immune-mediated cholestatic liver diseases [2]. Group 2: Clinical Developments - Analysts believe that volixibat could launch as early as the first half of 2027, with the VISTAS study in primary sclerosing cholangitis expected to provide topline data in Q2 2026 [2]. - Enrollment for the VISTAS study is anticipated to be completed in the second half of 2026, indicating a critical timeline for the company's product development [2]. Group 3: Stock Performance and Analyst Ratings - Over the past six months, MIRM shares have increased by over 91%, with all 11 analysts covering the stock rating it as a Buy [3]. - The median price target among analysts is set at $103, suggesting a slight upside of just under 4%, while H.C. Wainwright's target of $130 implies an upside potential of almost 31% [3]. Group 4: Company Overview - Mirum Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing therapies for rare and orphan diseases [3].